Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants

QTc Interval Reference Values and Their (Non)-Maturational Factors in Neonates and Infants: A Systematic Review

QTc interval measurement is a widely used screening tool to assess the risk of cardiac diseases, arrhythmias, and is a useful biomarker for pharmacovigilance. However, the interpretation of QTc is difficult in neonates due to hemodynamic maturational changes and uncertainties on reference values. To describe trends in QTc values throughout infancy (1 year of life), and to explore the impact of (non)-maturational changes and medicines exposure, a structured systematic review (PROSPERO CRD42022302296) was performed. In term neonates, a decrease was observed over the first week of life, whereafter values increased until two months of age, followed by a progressive decrease until six months. A similar pattern with longer QTc values was observed in preterms. QTc is influenced by cord clamping, hemodynamic changes, therapeutic hypothermia, illnesses and sleep, not by sex. Cisapride, domperidone and doxapram result in QTc prolongation in neonates. Further research in this age category is needed to improve primary screening practices and QTcthresholds, earlier detection of risk factors and precision pharmacovigilance.

Deglycosylated Azithromycin Targets Transgelin to Enhance Intestinal Smooth Muscle Function

Azithromycin (AZM) has been widely used as an antibacterial drug for many years. It has also been used to treat delayed gastric emptying. However, it exerts several side effects. We found that deglycosylated AZM (Deg-AZM or CP0119), an AZM metabolite, is a positively strong intestinal agonist that may result in the intestinal mobility experienced by patients after AZM administration. We confirmed that Deg-AZM can function strongly on intestinal peristalsis and identified transgelin as its potential molecular target. Furthermore, our pharmacological studies showed that the binding of Deg-AZM to transgelin enhanced the contractility of intestinal smooth muscle cells by facilitating the assembly of actin filaments into tight bundles and stress fibers. Specifically, Deg-AZM promoted intestinal peristaltic activity in wild-type mice but not in transgelin (-/-) mice. Moreover, Deg-AZM did not exert antibacterial activity and did not disrupt intestinal flora. Thus, Deg-AZM may become a potential drug for slow-transit constipation treatment.

Nonpharmacological management of gastroesophageal reflux in preterm infants

Gastroesophageal reflux (GOR) is very common among preterm infants, due to several physiological mechanisms. Although GOR should not be usually considered a pathological condition, its therapeutic management still represents a controversial issue among neonatologists; pharmacological overtreatment, often unuseful and potentially harmful, is increasingly widespread. Hence, a stepwise approach, firstly promoting conservative strategies such as body positioning, milk thickening, or changes of feeding modalities, should be considered the most advisable choice in preterm infants with GOR. This review focuses on the conservative management of GOR in the preterm population, aiming to provide a complete overview, based on currently available evidence, on potential benefits and adverse effects of nonpharmacological measures. Nonpharmacological management of GOR might represent a useful tool for neonatologists to reduce the use of antireflux medications, which should be limited to selected cases of symptomatic babies.

Pharmacological therapy of gastroesophageal reflux in preterm infants

Although gastroesophageal reflux (GER) is a very common phenomenon among preterm infants, its therapeutic management is still an issue of debate among neonatologists. A step-wise approach should be advisable, firstly promoting nonpharmacological interventions and limiting drugs to selected infants unresponsive to the conservative measures or who are suffering from severe GER with clinical complications. Despite of this, a concerning pharmacological overtreatment has been increasingly reported. Most of the antireflux drugs, however, have not been specifically assessed in preterm infants; moreover, serious adverse effects have been noticed in association to their administration. This review mainly aims to draw the state of the art regarding the pharmacological management of GER in preterm infants, analyzing the best piecies of evidence currently available on the most prescribed anti-reflux drugs. Although further trials are required, sodium alginate-based formulations might be considered promising; however, data regarding their safety are still limited. Few piecies of evidence on the efficacy of histamine-2 receptor blockers and proton pump inhibitors in preterm infants with GER are currently available. Nevertheless, a significantly increased risk of necrotizing enterocolitis and infections has been largely reported in association with their use, thereby leading to an unfavorable risk-benefit ratio. The efficacy of metoclopramide in GER's improvement still needs to be clarified. Other prokinetic agents, such as domperidone and erythromycin, have been reported to be ineffective, whereas cisapride has been withdrawn due to its remarkable cardiac adverse effects.

Cardiovascular phenotype in extremely low birth weight infants: long-term consequences

Low birth weight, a possible consequence of prematurity at birth or intrauterine growth restriction, has been recently recognized as an emerging risk factor to develop cardiovascular (CV) future adverse events. Our aim was to perform a short review about the studies conducted in order to evaluate the CV risk profile of a specific subpopulation of infants suffering from low birth weight, that is those having a birth weight less than 1,000 g, called extremely low birth weight.

An algorithm for QT interval monitoring in neonatal intensive care units

QT surveillance of neonatal patients, and especially premature infants, may be important because of the potential for concomitant exposure to QT-prolonging medications and because of the possibility that they may have hereditary QT prolongation (long-QT syndrome), which is implicated in the pathogenesis of approximately 10% of sudden infant death syndrome. In-hospital automated continuous QT interval monitoring for neonatal and pediatric patients may be beneficial but is difficult because of high heart rates; inverted, biphasic, or low-amplitude T waves; noisy signal; and a limited number of electrocardiogram (ECG) leads available. Based on our previous work on an automated adult QT interval monitoring algorithm, we further enhanced and expanded the algorithm for application in the neonatal and pediatric patient population. This article presents results from evaluation of the new algorithm in neonatal patients. Neonatal-monitoring ECGs (n = 66; admission age range, birth to 2 weeks) were collected from the neonatal intensive care unit in 2 major teaching hospitals in the United States. Each digital recording was at least 10 minutes in length with a sampling rate of 500 samples per second. Special handling of high heart rate was implemented, and threshold values were adjusted specifically for neonatal ECG. The ECGs studied were divided into a development/training ECG data set (TRN), with 24 recordings from hospital 1, and a testing data set (TST), with 42 recordings composed of cases from both hospital 1 (n = 16) and hospital 2 (n = 26). Each ECG recording was manually annotated for QT interval in a 15-second period by 2 cardiologists. Mean and standard deviation of the difference (algorithm minus cardiologist), regression slope, and correlation coefficient were used to describe algorithm accuracy. Considering the technical problems due to noisy recordings, a high fraction (approximately 80%) of the ECGs studied were measurable by the algorithm. Mean and standard deviation of the error were both low (TRN = -3 +/- 8 milliseconds; TST = 1 +/- 20 milliseconds); regression slope (TRN = 0.94; TST = 0.83) and correlation coefficients (TRN = 0.96; TST = 0.85) (P < .0001) were fairly high. Performance on the TST was similar to that on the TRN with the exception of 2 cases. These results confirm that automated continuous QT interval monitoring in the neonatal intensive care setting is feasible and accurate and may lead to earlier recognition of the "vulnerable" infant.

The effect of body positioning on gastroesophageal reflux in premature infants: evaluation by combined impedance and pH monitoring

OBJECTIVE

To evaluate the pattern of acid and nonacid gastroesophageal reflux (GER) in different body positions in preterm infants with reflux symptoms by a combined multichannel intraluminal impedance (MII)-pH monitoring, which identifies both acid and nonacid GER.

STUDY DESIGN

Premature infants with frequent regurgitation and postprandial desaturation (n = 22) underwent a 24-hour recording of MII-pH. In a within-subjects design, reflux indexes were analyzed with the infants in 4 different positions: supine (S), prone (P), on the right side (RS), and on the left side (LS).

RESULTS

All infants were analyzed for 20 hours. The mean number of recorded GER episodes was 109.7. The mean esophageal exposure to acid and nonacid GER was lower in positions P (4.4% and 0.3%, respectively) and LS (7.5% and 0.7%, respectively) than in positions RS (21.4% and 1.2%, respectively) and S (17.6% and 1.3%, respectively). The number of postprandial nonacid GER episodes decreased but the number of acid GER episodes increased over time. The LS position showed the lowest esophageal acid exposure (0.8%) in the early postprandial period, and the P position showed the lowest esophageal acid exposure (5.1%) in the late postprandial period.

CONCLUSION

Placing premature infants in the prone or left lateral position in the postprandial period is a simple intervention to limit GER.

High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants

BACKGROUND & AIMS

Feeding intolerance because of functional gastrointestinal dysmotility and parenteral nutrition-associated cholestasis (PNAC) are common problems in preterm, very-low-birth-weight (VLBW) infants. This double-blind, randomized, placebo-controlled study aimed to assess the effectiveness of "high-dose" oral erythromycin as a prokinetic agent in decreasing the incidence of PNAC. Two secondary end points, including the time to achieve full enteral feeding and the duration of parenteral nutrition, were also evaluated.

METHODS

Infants consecutively admitted to the neonatal unit were randomized to receive erythromycin (12.5 mg/kg/dose every 6 hours for 14 days) or an equivalent volume of normal saline (placebo) if they attained less than half the total daily fluid intake (<75 mL/kg/day) as milk feeds on day 14 of life.

RESULTS

Of 182 VLBW infants enrolled, 91 received erythromycin. The incidence of PNAC was significantly lower in erythromycin-treated infants (18/91) compared with placebo infants (37/91; P = .003). Treated infants achieved full enteral nutrition significantly earlier (mean, 10.1; SE, 1.7 days; P < .001), and the duration of parenteral nutrition was also significantly decreased by 10 days (P < .001). Importantly, fewer infants receiving erythromycin had 2 or more episodes of septicemia (n = 4) compared with placebo patients (n = 13, P = .03). No serious adverse effect was associated with erythromycin treatment.

CONCLUSIONS

High-dose oral erythromycin can be considered as a rescue measure for VLBW infants who fail to establish adequate enteral nutrition and in whom anatomically obstructive pathologies of the gastrointestinal tract have been excluded.

N/A

N/A